Observ prosp study of acalabrutinib in CLL therapy in real clinical practice in Belarus

Trial Identifier:	D8220R00090
Sponsor:	AstraZeneca
Start Date:	December 2025
Primary Completion Date:	December 2029
Study Completion Date:	December 2029
Condition:	CLL (Chronic Lymphocytic Leukemia)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

No locations posted.

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.